1. Introduction {#s1}
===============

Degenerative aortic valve stenosis is a very common valvular heart disorder in adults aged \> 65 years in industrialized countries, with a prevalence rate of 3%--9%.[@b1],[@b2] Surgical aortic valve replacement (SAVR) has been the standard of care for these patients. However, at least one third of the patients are considered too high at risk or inoperable for SAVR due to multiple comorbidities. In the last decade, transcatheter aortic valve implantation (TAVI) has emerged as a less-invasive treatment for these patients with \> 300,000 procedures performed to date. Importantly, its use is still growing,[@b3]--[@b6] as the field of TAVI is rapidly evolving due to improvements in catheter and valve technology, procedural techniques and refined patient selection. Consequently, knowledge of long-term structural device integrity and patient-reported outcomes are important to guide this development.[@b7],[@b8]

Most patients undergoing TAVI are octogenarians with multiple co-morbidities and reduced health related quality of life (QoL).[@b9] In these patients, the importance of QoL may be as or even more important than survival.[@b10],[@b11] Moreover, meaningful long-term benefit of QoL post-TAVI is of importance to guide patient-centered decision-making as well as identifying predictors for improvement of QoL post-TAVI. Yet, information on true long-term results is lacking.

Accordingly, we initiated study on the long-term integrity of the self-expanding Medtronic CoreValve System (Medtronic Inc. Minneapolis MN) to analyse QoL and functional health status at a minimum of 4 years after TAVI.[@b12]

The main objective of this sub-study is to investigate long-term health related quality of life and functional health status. A sub-analysis was performed to compare QoL of participants with the general age matched Dutch population.

2. Methods {#s2}
==========

Between November 2005 and March 2012, a total of 259 patients with severe symptomatic aortic valve stenosis received a TAVI in the Erasmus Medical Centre, Rotterdam. After checking survival status in January 2016 at the Municipal Civil Registry, survivors were evaluated for assessment of long-term valve function (transthoracic echocardiography) and frame integrity of the self-expanding CoreValve (Multi Slice Computed Tomography―TACT study).[@b12]

Only patients who underwent TAVI \> 4 years earlier were eligible. Given the nature of the study that included MSCT, patients with renal failure, known hypersensitivity or contraindication to intravenous contrast in addition to patients with previous stroke, a language barrier and treatment with a valve other than the self-expanding CoreValve were not included in the present study. Patients who fulfilled these study-criteria were contacted for both long-term valve & frame analysis and health-related status. The Medical Ethics Committee approved the study (MEC-2013-331) and all participants signed the informed consent. After written informed consent, patients were scheduled for a one-day out-patient visit during which data on valve function, health status and QoL were collected. A sub-analysis was performed to compare the measured health related QoL at follow-up in TACT patients with the general Dutch population as stratified by age \> 70 years. No data on baseline QoL was available.

2.1. Baseline characteristics {#s2a}
-----------------------------

Socio-demographic characteristics included gender and age. Cardiovascular risk factors included: diabetes mellitus, hypertension, pulmonary vascular disease, previous stroke, atrial fibrillation, previous pacemaker, chronic obstructive pulmonary disease, pulmonary hypertension and chronic kidney disease. Clinical characteristics included: history of coronary artery disease, peak aortic valve velocity, left ventricular ejection fraction, NYHA classification and Log EuroSCORE (European System for Cardiac Operative Risk Evaluation). All data on baseline and the medical history of patients were collected from the medical records.

2.2. Health status {#s2b}
------------------

Health-related QoL was measured with the generic Short Form 36 Health Survey (SF-36) and the EuroQoL-5-dimensions-5 levels (EQ-5D-5L) questionnaires. The SF-36 questionnaire is a validated and widely accepted instrument to measure overall physical and mental health status. It consists of 36 items, which measures eight health-related dimensions covering physical functioning, role physical, bodily pain, general health, role emotional, social functioning, vitality and mental health. Each item is scored in a 0--100 range, with higher scores reflecting a better QoL.[@b13]

The EQ-5D-5L is a generic health utility QoL instrument and is qualified for measuring health status within an elderly population (EuroQoL Group, Rotterdam, The Netherlands).[@b14] This descriptive system consists of five domains (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which is divided in five levels of functioning \[i.e., no problems (level 1), some or moderate problems (level 2 and 3), and severe or extreme problems (level 4 and 5)\]. Theoretically, 3125 different health status can be generated by this classification, which can be converted to a utility score, ranging from ?0.446 to 1 (a value of 1 indicating full health, while a value lower than 0 represents a status considered to be worse than death). The second part of the EQ-5D includes a visual analog scale (EQ-VAS), ranging from 0 ("Worst imaginable health state") to 100 ("Best imaginable health state").[@b15] Both SF-36 and EQ-5D, questionnaires were administered and collected during in-person visits \> 4 years after TAVI.

2.3. Statistical analysis {#s2c}
-------------------------

Continuous variables are expressed as mean ± SD. Dichotomous variables are presented as numbers and percentages. To evaluate differences between TACT participants and surviving non-participants chi-square tests, students *t*-test or Mann-Whitney tests were applied as appropriate. *P* \< 0.05 was considered statistically significant. All analyses were performed using SPSS version 21 for Windows (SPSS Inc, Chicago, IL).

3. Results {#s3}
==========

3.1. Patient characteristics {#s3a}
----------------------------

Of the 259 patients who underwent TAVI between 2005 and 2012, 158 (61%) patients died before the time of inclusion (January 2016) with a mean survival time for the total cohort of 4.7 years (95% CI: 4.16--5.14). Out of the 101 remaining patients, 81 patients did not participate in the TACT study due to exclusion criteria or non-response. Other reasons were the lack of social support or due to physical or mental disabilities. The remaining 20 patients with a mean follow-up period of 5.5 years (range 4--10 years) provided written informed consent and were included in the current analysis ([Figure 1](#jgc-15-04-261-g001){ref-type="fig"}).

![Study flowchart of number of total TAVI patients between 2005 and 2012, non-responders (*n* = 81) and the final study population with more than 4 years follow-up data post-TAVI (*n* = 20).\
TAVI: transcatheter aortic valve implantation.](jgc-15-04-261-g001){#jgc-15-04-261-g001}

Baseline data of all 101 patients are shown in [Table 1](#jgc-15-04-261-t01){ref-type="table"}, including a comparison between participants (*n* = 20) in the TACT sub-study and surviving non-participants (*n* = 81). Most patients suffered from multiple comorbidities and high surgical risk (mean logistic EuroSCORE 15.4% ± 9.8%). The mean age at the time of TAVI was 80 ± 8.0 years, and almost half were men. The majority of participants (77%) had a poor functional status (NYHA III/IV) before TAVI. Overall, there were no significant differences on baseline characteristics between participants and surviving non-participants, except for left ventricular ejection fraction (LVEF).

###### Baseline patient characteristics.

                                 Total population (*n* = 101)   Non-participants (*n* = 81)   Participants (*n* = 20)   *P*-value
  ----------------------------- ------------------------------ ----------------------------- ------------------------- -----------
  Mean age, yrs                           79.7 ± 8.0                    80.2 ± 8.0                  77.9 ± 7.7            0.26
  Male sex                                 49 (49%)                      38 (47%)                    11 (55%)             0.52
  Body mass index, kg/m^2^                26.8 ± 3.9                    26.5 ± 3.4                  27.9 ± 5.3            0.16
  Cardiovascular risk factors                                                                                          
   Diabetes mellitus                       21 (21%)                      18 (22%)                     3 (15%)             0.48
   Hypertension                            60 (59%)                      47 (58%)                    13 (65%)             0.57
   PVD                                      8 (8%)                        7 (9%)                      1 (5%)              0.59
   Previous stroke                         20 (20%)                      15 (19%)                     5 (25%)             0.52
   Atrial fibrillation                     22 (22%)                      17 (21%)                     5 (25%)             0.70
   Previous pacemaker                      12 (12%)                       9 (11%)                     3 (15%)             0.63
   COPD                                    21 (21%)                      15 (19%)                     6 (30%)             0.26
   PHT                                      7 (7%)                        5 (6%)                      2 (10%)             0.55
   Chronic kidney disease                  16 (16%)                      12 (15%)                     4 (20%)             0.57
  History of CAD                           50 (50%)                      38 (47%)                    12 (60%)             0.30
  Peak AoV, m/s                           4.3 ± 0.8                      4.3 ± 0.8                   4.3 ± 0.9            0.75
  LVEF                                  51.7% ± 14.1%                  53.7% ± 12.7%               44.4% ± 17.0%          0.01
  NYHA classification                                                                                                     0.30
   I / II                                  23 (23%)                      20 (25%)                     3 (15%)          
   III / IV                                78 (77%)                      61 (75%)                    17 (85%)          
  Logistic EuroSCORE                     15.4% ± 9.8%                  14.5% ± 9.5%                18.9% ± 10.8%          0.07

Data are presented as mean ± SD or *n* (%) unless other indicated. AoV: Aortic valve velocity; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; EuroSCORE: European System for Cardiac Operative Risk Evaluation; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; PHT: pulmonary hypertension; PVD: pulmonary vascular disease.

3.2. (Post-) Procedural outcomes {#s3b}
--------------------------------

On post-procedural outcomes no differences between participants and non-participants were found. As shown in [Table 2](#jgc-15-04-261-t02){ref-type="table"}, all participants underwent successful TAVI with femoral access, general anesthesia as standard of care at that time, a mean procedure time of 203 ± 64.7 min and a mean hospitalization time of 10.4 ± 7.6 days. Post-procedural complications included one participant with a major vascular complication and four participants who required a permanent pacemaker. Major bleeding after more than one day occurred in six participants of which two were life threatening.

###### Procedural and post-procedural outcomes.

                                  Total population (*n* = 101)   Non-participants (*n* = 81)   TACT-participants (*n* = 20)   *P*-value
  ------------------------------ ------------------------------ ----------------------------- ------------------------------ -----------
  **Procedural outcomes**                                                                                                    
   Access trans femoral                    100 (99%)                      80 (99%)                      20 (100%)               0.62
   Pre-dilatation                           97 (98%)                      78 (98%)                       19 (95%)               0.49
   MCV                                      97 (96%)                      77 (95%)                      20 (100%)               0.31
   Device success                           98 (97%)                      78 (98%)                      20 (100%)               0.38
   Post-dilatation                          14 (14%)                       9 (11%)                       5 (25%)                0.11
   Total contrast, cc                      135 ± 68.5                   132.9 ± 69.1                   146.3 ± 66.7             0.47
   Procedure time                          193 ± 65.0                   190.9 ± 65.3                   203.4 ± 64.7             0.47
  **Post-procedural outcomes**                                                                                               
   Aortic valve regurgitation                                                                                                   0.58
    Mild                                    27 (27%)                      22 (28%)                       5 (25%)             
    Moderate/severe                          6 (6%)                        4 (5%)                        2 (10%)             
   Permanent pacemaker                      15 (15%)                      11 (14%)                       4 (20%)                0.47
   Bleeding more than 1 day                                                                                                     0.85
    Minor                                    9 (9%)                        7 (9%)                        2 (10%)             
    Major                                   11 (11%)                       9 (11%)                       2 (10%)             
    Life threatening                         6 (6%)                        4 (5%)                        2 (10%)             
   Major vascular complication               6 (6%)                        5 (6%)                         1 (5%)                0.58
   Place of discharge                                                                                                           0.61
    Home                                    91 (90%)                      71 (88%)                      20 (100%)            
    Other location                          10 (10%)                      10 (12%)                        0 (0%)             
   Length of stay, days                    9.2 ± 5.1                      9.0 ± 4.3                     10.4 ± 7.6              0.28

Data are presented as mean ± SD or *n* (%) unless other indicated. MCV: Medtronic CoreValve.

3.3. Health status {#s3c}
------------------

The SF-36, EQ-5D-5L and EQ-VAS scores are shown in [Table 3](#jgc-15-04-261-t03){ref-type="table"}. The mean SF-36 subscale scores at follow-up were physical functioning 40.8 ± 26.3, role physical functioning 67.7 ± 34.9, vitality 54.6 ± 21.6, general health 52.1 ± 20.4, social functioning 63.8 ± 37.7, role emotional functioning 70.2 ± 36.0, mental health 73.2 ± 23.3 and bodily pain 80.9 ± 22.9. With attention to EQ-5D, mobility was found to be the most frequent reported limitation (75%) while self-care was the least frequent reported limitation (35%). The majority of the participants had moderate limitations in all sub-domains. The mean utility index and EQ-VAS score were 0.69 ± 0.29 and 64.7 ± 15.1. [Table 3](#jgc-15-04-261-t03){ref-type="table"} also shows a comparison of the QoL in TACT participants with the mean QoL values of the age adjusted Dutch population. With respect to functional class expressed by NYHA, 80% had mild symptoms (class I or II) at follow-up versus 15% before TAVI, indicating a significant functional improvement ([Table 1](#jgc-15-04-261-t01){ref-type="table"} and [3](#jgc-15-04-261-t03){ref-type="table"}).

###### Quality of Life Scores at follow-up (6 years) in TACT-participants.

                                                TACT-subgroup (*n* = 20)   Dutch population\*
  -------------------------------------------- -------------------------- --------------------
  SF-36                                                                   
   Physical functioning                               40.8 ± 26.3             58.9 ± 30.8
   Role physical functioning                          67.7 ± 34.9             56.9 ± 44.0
   Vitality                                           54.6 ± 21.6             61.8 ± 23.6
   General health                                     52.1 ± 20.4             58.9 ± 21.1
   Social functioning                                 63.8 ± 37.7             75.6 ± 27.0
   Role emotional functioning                         70.2 ± 36.0             74.5 ± 38.2
   Mental health                                      73.2 ± 23.3             73.0 ± 19.9
   Bodily pain                                        80.9 ± 22.9             68.1 ± 27.4
  EQ-5D (% of patients indicating a problem)                              
   Mobility                                              75.0%                   36.5%
   Self-care                                             35.0%                   11.7%
   Usual activities                                      65.0%                   26.0%
   Pain/discomfort                                       60.0%                   48.5%
   Anxiety/depression                                    40.0%                    3.6%
   Utility score                                      0.69 ± 0.29             0.85 ± 0.15
   VAS                                                64.7 ± 15.1             72.9 ± 24.3
  NYHA classification                                                     
   I/II                                                 16 (80%)          
   III/IV                                               4 (20%)           

Data are presented as mean ± SD or *n* (%) unless other indicated. \*Dutch population norms for the SF-36 are stratified by age \> 70 years;[@b29] Dutch population norms for the EQ-5D are stratified by age \> 75 years.[@b15] EQ-5D: EuroQoL 5 Dimensions; SF-36: Short Form (36) Health Survey; VAS: Visual Analogue Score.

4. Discussion {#s4}
=============

The main findings of the present study in a selected group of octogenarians who underwent TAVI \> 4 years ago because of severe AS are a significant improvement in functional class (NYHA) and a satisfactory QoL.

Although we recognize that the herein included patients represent a selected group of TAVI patients, this study confirms the improvements reported in other studies but over a longer period of time.[@b16]--[@b18] Indeed, previous studies mainly focus on the first post-procedural period (up to one year) while in this study the mean follow-up time was 5.5 years. The improvement in functional class and the findings in health related outcome is noteworthy given the age and comorbid conditions in these patients. In line with others, sustainable improvement of NYHA class has been observed in long-term survivors, as NYHA class I/II has been observed in most patients, who were in NYHA III/IV prior to TAVI.[@b19],[@b20] This indicates that these patients, despite multiple comorbid conditions and advanced age, clearly benefit from this invasive procedure.

With respect to health-related QoL, the majority of the participants showed satisfactory QoL scores \> 4 years after TAVI. In addition, our study reveals a lower QoL when compared with the general age adjusted Dutch population.[@b15] Ware, *et al*.[@b21] described that a 5-point difference between groups or a 5-point change over time is considered clinically and socially relevant. Our participants scored lower on most SF-36 subscales and all EQ-5D subdomains when compared to the Dutch population as stratified by age \> 70 years.[@b15],[@b22] The differences in health scores on the physical scales of the SF-36 are more than five points and therefore should be considered clinically and socially relevant. With attention to bodily pain, the participants scored higher on the SF-36 subscale. A possible explanation is that patients are getting used to their physical limitations and multiple comorbidities,[@b23],[@b24] which could result in a lower sensitivity for pain. These findings indicate that within elderly people, large QoL differences exist and may under scribe the need for more long-term follow-up research, with standardized QoL instruments specific developed for patients with AS.

In comparison, the Partner study was the first to show a substantial improvement of QoL at 1-year follow-up after either TAVI or SAVR in high-risk elderly patients.[@b25] Baseline EQ-5D utility score increased by 14% to 0.66 at 1-year post-TAVI. Fairbairn, *et al*.[@b18] had shown that QoL, as measured with the EQ-5D and EQ-VAS, improved early after TAVI and was maintained at 1-year post-TAVI. The German TAVI registry revealed that patients with a low baseline EQ-5D had a significantly better improvement in QoL one year after TAVI.[@b17]

Other studies also showed a significant improvement at one-year follow-up in all SF-36 domains with higher summary scale scores than the general population-norms.[@b26],[@b27] Unfortunately, we could not perform an age- and co-morbidity matched comparison precluding firm conclusions or interpretation. Of note, the mean age of the reference data in the general Dutch population is standardized to 70+ whereas the mean age in our population was 79.7 years. It is important to note that an increase in age is associated with a decrease in QoL, indicating a decline in the slope of people\'s self-rated health over the decades of their life.[@b15] Mangen, *et al*.[@b28] reported that impairment increases rapidly with age, but health status is also associated with socio-demographic variables and comorbidities. These findings are consistent with our findings that increasing age and multiple co-morbidities can be associated with lower QoL.

4.1. Limitations {#s4a}
----------------

Our study is a single-center study and based on a small group of selected patients (20 participants of long-term survivors) most likely representing a group of most vital patients who agreed to participate in a clinical research project. Therefore selection bias may have occurred. Second, our analyses are based on a population including the first TAVI patients in the Netherlands. All procedures were performed under general anesthesia in patients with an extremely high-risk status and therefore might not represent a contemporary TAVI population.

4.2. Conclusions {#s4b}
----------------

This sub-study in a selected group of very elderly patients who underwent frame analysis assessment ≥ 4 years after TAVI reports significant improvement in functional class (NYHA). Furthermore, all patients showed a satisfactory quality of life despite their age and multiple comorbidities. In addition, our study reveals a lower QoL when compared with the general age matched Dutch population. The observed improvement in functional status reflects a positive long-term outcome of TAVI in this selected group of octogenarians. These benefits should be taken into account when discussing the indication for elderly patients undergoing TAVI. Further research is warranted on long-term health-related QoL in a high-risk population with aortic stenosis.
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